Lisata Therapeutics Inc
LSTA2.060USD
+0.050+2.49%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
18.04MMarket Cap
LossP/E TTM
More Details of Lisata Therapeutics Inc Company
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Lisata Therapeutics Inc Info
Ticker SymbolLSTA
Company nameLisata Therapeutics Inc
IPO dateNov 03, 1995
CEOMazzo (David J)
Number of employees26
Security typeOrdinary Share
Fiscal year-endNov 03
Address110 Allen Road
CityBASKING RIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07920
Phone19082292590
Websitehttps://www.lisata.com/
Ticker SymbolLSTA
IPO dateNov 03, 1995
CEOMazzo (David J)
Company Executives of Lisata Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David J. Mazzo, Ph.D.
Dr. David J. Mazzo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
264.69K
+3.26%
Dr. Kristen K. Buck, M.D.
Dr. Kristen K. Buck, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
79.79K
--
Dr. Mohammad Azab, M.D.
Dr. Mohammad Azab, M.D.
Independent Director
Independent Director
52.28K
+23.92%
Mr. Steven Mark (Steve) Klosk, J.D.
Mr. Steven Mark (Steve) Klosk, J.D.
Independent Director
Independent Director
49.57K
+8.05%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
49.41K
+8.07%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
39.48K
+10.31%
Mr. Tariq Imam
Mr. Tariq Imam
Senior Vice President, Business Development and Operations and General Counsel
Senior Vice President, Business Development and Operations and General Counsel
24.58K
--
Mr. James Nisco
Mr. James Nisco
Senior Vice President - Finance and Treasury, Chief Accounting Officer
Senior Vice President - Finance and Treasury, Chief Accounting Officer
23.49K
--
Mr. John D. Menditto
Mr. John D. Menditto
Vice President - Investor Relations & Corporate Communications
Vice President - Investor Relations & Corporate Communications
--
--
Ms. Cynthia L. Flowers
Ms. Cynthia L. Flowers
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David J. Mazzo, Ph.D.
Dr. David J. Mazzo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
264.69K
+3.26%
Dr. Kristen K. Buck, M.D.
Dr. Kristen K. Buck, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
79.79K
--
Dr. Mohammad Azab, M.D.
Dr. Mohammad Azab, M.D.
Independent Director
Independent Director
52.28K
+23.92%
Mr. Steven Mark (Steve) Klosk, J.D.
Mr. Steven Mark (Steve) Klosk, J.D.
Independent Director
Independent Director
49.57K
+8.05%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
49.41K
+8.07%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
39.48K
+10.31%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 23
Updated: Sun, Nov 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ruoslahti (Erkki)
12.50%
The Vanguard Group, Inc.
3.07%
Mazzo (David J)
3.00%
Renaissance Technologies LLC
1.32%
BML Capital Management LLC
1.25%
Other
78.86%
Shareholders
Shareholders
Proportion
Ruoslahti (Erkki)
12.50%
The Vanguard Group, Inc.
3.07%
Mazzo (David J)
3.00%
Renaissance Technologies LLC
1.32%
BML Capital Management LLC
1.25%
Other
78.86%
Shareholder Types
Shareholders
Proportion
Individual Investor
19.68%
Investment Advisor
5.55%
Hedge Fund
1.35%
Investment Advisor/Hedge Fund
1.23%
Venture Capital
0.13%
Research Firm
0.12%
Other
71.94%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
37
798.92K
9.06%
-27.67K
2025Q2
48
2.52M
29.29%
-66.93K
2025Q1
50
2.57M
30.49%
+155.41K
2024Q4
48
2.39M
27.90%
-46.00K
2024Q3
48
2.33M
27.50%
-84.74K
2024Q2
59
2.31M
27.35%
-158.27K
2024Q1
60
2.32M
28.57%
+1.21M
2023Q4
63
2.13M
26.53%
+1.00M
2023Q3
72
2.18M
28.45%
+396.20K
2023Q2
72
2.18M
28.62%
+428.28K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ruoslahti (Erkki)
1.10M
12.6%
-78.14K
-6.62%
Apr 17, 2025
The Vanguard Group, Inc.
254.18K
2.9%
--
--
Jun 30, 2025
Mazzo (David J)
264.69K
3.02%
+8.35K
+3.26%
Apr 17, 2025
Renaissance Technologies LLC
102.82K
1.17%
+100.00
+0.10%
Jun 30, 2025
BML Capital Management LLC
209.81K
2.4%
-7.04K
-3.25%
Jun 30, 2025
Buck (Kristen K)
79.79K
0.91%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
61.08K
0.7%
+553.00
+0.91%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
54.86K
0.63%
--
--
Jun 30, 2025
Azab (Mohammad)
52.28K
0.6%
+10.09K
+23.92%
Apr 17, 2025
Klosk (Steven Mark)
49.57K
0.57%
+3.69K
+8.05%
Apr 17, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Date
Type
Ratio
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
FAQs
Who are the top five shareholders of Lisata Therapeutics Inc?
The top five shareholders of Lisata Therapeutics Inc are:
Ruoslahti (Erkki) holds 1.10M shares, accounting for 12.60% of the total shares.
The Vanguard Group, Inc. holds 254.18K shares, accounting for 2.90% of the total shares.
Mazzo (David J) holds 264.69K shares, accounting for 3.02% of the total shares.
Renaissance Technologies LLC holds 102.82K shares, accounting for 1.17% of the total shares.
BML Capital Management LLC holds 209.81K shares, accounting for 2.40% of the total shares.
Ruoslahti (Erkki) holds 1.10M shares, accounting for 12.60% of the total shares.
The Vanguard Group, Inc. holds 254.18K shares, accounting for 2.90% of the total shares.
Mazzo (David J) holds 264.69K shares, accounting for 3.02% of the total shares.
Renaissance Technologies LLC holds 102.82K shares, accounting for 1.17% of the total shares.
BML Capital Management LLC holds 209.81K shares, accounting for 2.40% of the total shares.
What are the top three shareholder types of Lisata Therapeutics Inc?
The top three shareholder types of Lisata Therapeutics Inc are:
Ruoslahti (Erkki)
The Vanguard Group, Inc.
Mazzo (David J)
Ruoslahti (Erkki)
The Vanguard Group, Inc.
Mazzo (David J)
How many institutions hold shares of Lisata Therapeutics Inc (LSTA)?
As of 2025Q3, 37 institutions hold shares of Lisata Therapeutics Inc, with a combined market value of approximately 798.92K, accounting for 9.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -20.23%.
What is the biggest source of revenue for Lisata Therapeutics Inc?
In --, the -- business generated the highest revenue for Lisata Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
